Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell

Volumn 171, Issue 4, 2017, Pages 934-949.e15

  Riaz, Nadeem ^a   Havel, Jonathan J ^a   Makarov, Vladimir ^a   Desrichard, Alexis ^a   Urba, Walter J ^b   Sims, Jennifer S ^a   Hodi, F Stephen ^c   Martín Algarra, Salvador ^d   Mandal, Rajarsi ^a   Sharfman, William H ^e   Bhatia, Shailender ^f   Hwu, Wen Jen ^g   Gajewski, Thomas F ^h   Slingluff, Craig L ⁱ   Chowell, Diego ^a   Kendall, Sviatoslav M ^a   Chang, Han ^j   Shah, Rachna ^a   Kuo, Fengshen ^a   Morris, Luc G T ^a   Sidhom, John William ^k   Schneck, Jonathan P ^k   Horak, Christine E ^j   Weinhold, Nils ^a   Chan, Timothy A ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

clonal evolution clonal selection; immunotherapy; ipilimumab; melanoma; neoantigen load; nivolumab; T cell receptor repertoire; tumor immune evasion; tumor microenvironment; tumor mutation load tumor mutation burden

Indexed keywords

ANTIGEN; IPILIMUMAB; NIVOLUMAB; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CLONAL EVOLUTION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; IMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 85031295254     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.09.028     Document Type: Article

References (73)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Arnaud-Haond, S., Duarte, C.M., Alberto, F., Serrão, E.A., Standardizing methods to address clonality in population studies. Mol. Ecol. 16 (2007), 5115–5139.
3. Arstila, T.P., Casrouge, A., Baron, V., Even, J., Kanellopoulos, J., Kourilsky, P., A direct estimate of the human alphabeta T cell receptor diversity. Science 286 (1999), 958–961.
4. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
5. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161 (2015), 1681–1696.
6. Carlson, C.S., Emerson, R.O., Sherwood, A.M., Desmarais, C., Chung, M.W., Parsons, J.M., Steen, M.S., LaMadrid-Herrmannsfeldt, M.A., Williamson, D.W., Livingston, R.J., et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun., 4, 2013, 2680.
7. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
8. Chen, P.L., Roh, W., Reuben, A., Cooper, Z.A., Spencer, C.N., Prieto, P.A., Miller, J.P., Bassett, R.L., Gopalakrishnan, V., Wani, K., et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6 (2016), 827–837.
9. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N.S., Cope, L.M., Snyder, A., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162 (2015), 974–986.
10. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
11. Dako (2016). PD-L1 IHC 28-8 pharmDx. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150027c.pdf.
12. Das, R., Verma, R., Sznol, M., Boddupalli, C.S., Gettinger, S.N., Kluger, H., Callahan, M., Wolchok, J.D., Halaban, R., Dhodapkar, M.V., Dhodapkar, K.M., Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194 (2015), 950–959.
13. Davoli, T., Uno, H., Wooten, E.C., Elledge, S.J., Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science, 355, 2017, eaaf8399.
14. DeWitt, W.S., Emerson, R.O., Lindau, P., Vignali, M., Snyder, T.M., Desmarais, C., Sanders, C., Utsugi, H., Warren, E.H., McElrath, J., et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89 (2015), 4517–4526.
15. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
16. Emerson, R., Sherwood, A., Desmarais, C., Malhotra, S., Phippard, D., Robins, H., Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data. J. Immunol. Methods 391 (2013), 14–21.
17. Ferris, R.L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375 (2016), 1856–1867.
18. Fisher, S., Barry, A., Abreu, J., Minie, B., Nolan, J., Delorey, T.M., Young, G., Fennell, T.J., Allen, A., Ambrogio, L., et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol., 12, 2011, R1.
19. Gordon, S.R., Maute, R.L., Dulken, B.W., Hutter, G., George, B.M., McCracken, M.N., Gupta, R., Tsai, J.M., Sinha, R., Corey, D., et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545 (2017), 495–499.
20. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
21. Hodi, F.S., Kluger, H., Sznol, M., Carvajal, R., Lawrence, D., Atkins, M., Powderly, J., Sharfman, W., Puzanov, I., Smith, D., et al. Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res., 76, 2016 CT001–CT001.
22. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
23. Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y., Fouse, S.D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 (2014), 189–193.
24. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
25. Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., Woo, G., Nguyen, A.V., Figueiredo, C.C., Foubert, P., et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539 (2016), 437–442.
26. Koboldt, D.C., Zhang, Q., Larson, D.E., Shen, D., McLellan, M.D., Lin, L., Miller, C.A., Mardis, E.R., Ding, L., Wilson, R.K., VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22 (2012), 568–576.
27. Landau, D.A., Tausch, E., Taylor-Weiner, A.N., Stewart, C., Reiter, J.G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526 (2015), 525–530.
28. Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W.H. Jr., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C.D., et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J. Clin. Oncol., 2017, 10.1200/JCO.2016.71.8023.
29. Larson, D.E., Harris, C.C., Chen, K., Koboldt, D.C., Abbott, T.E., Dooling, D.J., Ley, T.J., Mardis, E.R., Wilson, R.K., Ding, L., SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28 (2012), 311–317.
30. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
31. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
32. McGranahan, N., Favero, F., de Bruin, E.C., Birkbak, N.J., Szallasi, Z., Swanton, C., Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med., 7, 2015, 283ra54.
33. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
34. Morris, L.G., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A.A., Makarov, V., Reis-Filho, J.S., Chan, T.A., Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7 (2016), 10051–10063.
35. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., et al., CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
36. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., Alizadeh, A.A., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12 (2015), 453–457.
37. Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S.L., Lamberth, K., Buus, S., Brunak, S., Lund, O., Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12 (2003), 1007–1017.
38. Riaz, N., Morris, L., Havel, J.J., Makarov, V., Desrichard, A., Chan, T.A., The role of neoantigens in response to immune checkpoint blockade. Int. Immunol. 28 (2016), 411–419.
39. Riaz, N., Havel, J.J., Kendall, S.M., Makarov, V., Walsh, L.A., Desrichard, A., Weinhold, N., Chan, T.A., Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat. Genet. 48 (2016), 1327–1329.
40. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
41. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
42. Robins, H.S., Campregher, P.V., Srivastava, S.K., Wacher, A., Turtle, C.J., Kahsai, O., Riddell, S.R., Warren, E.H., Carlson, C.S., Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114 (2009), 4099–4107.
43. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
44. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., O'Donnell, P.H., Balmanoukian, A., Loriot, Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
45. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., Swanton, C., DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol., 17, 2016, 31.
46. Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., Shah, S.P., PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11 (2014), 396–398.
47. Salerno, E.P., Bedognetti, D., Mauldin, I.S., Deacon, D.H., Shea, S.M., Pinczewski, J., Obeid, J.M., Coukos, G., Wang, E., Gajewski, T.F., et al. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 5, 2016, e1240857.
48. Saunders, C.T., Wong, W.S., Swamy, S., Becq, J., Murray, L.J., Cheetham, R.K., Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28 (2012), 1811–1817.
49. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
50. Shen, R., Seshan, V.E., FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res., 44, 2016, e131.
51. Sims, J.S., Grinshpun, B., Feng, Y., Ung, T.H., Neira, J.A., Samanamud, J.L., Canoll, P., Shen, Y., Sims, P.A., Bruce, J.N., Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire. Proc. Natl. Acad. Sci. USA 113 (2016), E3529–E3537.
52. Six, A., Mariotti-Ferrandiz, M.E., Chaara, W., Magadan, S., Pham, H.P., Lefranc, M.P., Mora, T., Thomas-Vaslin, V., Walczak, A.M., Boudinot, P., The past, present, and future of immune repertoire biology - the rise of next-generation repertoire analysis. Front. Immunol., 4, 2013, 413.
53. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
54. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200ra116.
55. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
56. Sweis, R.F., Spranger, S., Bao, R., Paner, G.P., Stadler, W.M., Steinberg, G., Gajewski, T.F., Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4 (2016), 563–568.
57. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., Chen, L., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4, 2012, 127ra37.
58. Taube, J.M., Young, G.D., McMiller, T.L., Chen, S., Salas, J.T., Pritchard, T.S., Xu, H., Meeker, A.K., Fan, J., Cheadle, C., et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin. Cancer Res. 21 (2015), 3969–3976.
59. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
60. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16 (2016), 275–287.
61. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
62. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
63. Verdegaal, E.M., de Miranda, N.F., Visser, M., Harryvan, T., van Buuren, M.M., Andersen, R.S., Hadrup, S.R., van der Minne, C.E., Schotte, R., Spits, H., et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536 (2016), 91–95.
64. Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.J., et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48 (2016), 768–776.
65. Weber, J., Horak, C., Hodi, F.S., Chang, H., Woods, D., Sanders, C., Robins, H., Yusko, E., Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. Ann. Oncol., 27, 2016 1047O.
66. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol. Res. 4 (2016), 345–353.
67. Wei, L., Liu, L.T., Conroy, J.R., Hu, Q., Conroy, J.M., Morrison, C.D., Johnson, C.S., Wang, J., Liu, S., MAC: identifying and correcting annotation for multi-nucleotide variations. BMC Genomics, 16, 2015, 569.
68. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15 (2009), 7412–7420.
69. Yau, C., OncoSNP-SEQ: a statistical approach for the identification of somatic copy number alterations from next-generation sequencing of cancer genomes. Bioinformatics 29 (2013), 2482–2484.
70. Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P.W., Levine, D.A., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun., 4, 2013, 2612.
71. Yu, G., Wang, L.G., Han, Y., He, Q.Y., clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (2012), 284–287.
72. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
73. Zarnitsyna, V.I., Evavold, B.D., Schoettle, L.N., Blattman, J.N., Antia, R., Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. Front. Immunol., 4, 2013, 485.